The epidermal growth factor receptor pathway: a model for targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase frequently overexpressed in epithelial cancers.
• EGFR was the first receptor tyrosine kinase identified as a viable target for cancer therapy.
• Over two decades of research have led to the development of multiple anti-EGFR agents currently used in clinical practice.

Purpose of the Study:

• To review recent advances in understanding EGFR activation and function.
• To discuss the discovery of primary and secondary EGFR somatic mutations.
• To highlight new generations of anti-EGFR agents and their potential in cancer treatment.

Main Methods:

• Review of current literature on EGFR biology and targeted therapy.
• Analysis of clinical data on anti-EGFR agents.
• Discussion of emerging therapeutic strategies targeting EGFR.

Main Results:

• Significant progress has been made in elucidating EGFR activation mechanisms and functional roles.
• Identification of various EGFR somatic mutations (primary and secondary) influencing treatment response.
• Development of novel anti-EGFR agents with improved efficacy and resistance profiles.

Conclusions:

• EGFR remains a critical target in epithelial tumor therapy.
• Understanding EGFR mutations and developing next-generation inhibitors are crucial for optimizing treatment outcomes.
• Targeting EGFR serves as a potential model for developing therapies against other receptor tyrosine kinases.